Applied DNA Sciences to Restart Quarterly Investor Calls

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced it will resume regular quarterly investor calls. The company will start with the fiscal third quarter 2025 financial results report in mid-August. This decision aligns with the cancellation of the previously scheduled intra-quarter call for June 17, 2025.

Applied DNA focuses on using polymerase chain reaction (PCR) to develop and detect DNA technologies. Its operations span the enzymatic manufacture of synthetic DNA for nucleic acid-based therapeutics and the sale of proprietary RNA polymerase for mRNA therapeutics production. The company is also involved in molecular diagnostics and genetic testing services.